179 related articles for article (PubMed ID: 17969361)
21. Neurotrophic factors and amyotrophic lateral sclerosis.
Ekestern E
Neurodegener Dis; 2004; 1(2-3):88-100. PubMed ID: 16908980
[TBL] [Abstract][Full Text] [Related]
22. [Neurotrophic factors: basis for their clinical application].
Morís G; Vega JA
Neurologia; 2003; 18(1):18-28. PubMed ID: 12590377
[TBL] [Abstract][Full Text] [Related]
23. Phosphorylated Smad2/3 immunoreactivity in sporadic and familial amyotrophic lateral sclerosis and its mouse model.
Nakamura M; Ito H; Wate R; Nakano S; Hirano A; Kusaka H
Acta Neuropathol; 2008 Mar; 115(3):327-34. PubMed ID: 18210139
[TBL] [Abstract][Full Text] [Related]
24. Axon guidance proteins: novel therapeutic targets for ALS?
Schmidt ER; Pasterkamp RJ; van den Berg LH
Prog Neurobiol; 2009 Aug; 88(4):286-301. PubMed ID: 19523502
[TBL] [Abstract][Full Text] [Related]
25. A genetic fusion GDNF-C fragment of tetanus toxin prolongs survival in a symptomatic mouse ALS model.
Ciriza J; Moreno-Igoa M; Calvo AC; Yague G; Palacio J; Miana-Mena FJ; Muñoz MJ; Zaragoza P; Brûlet P; Osta R
Restor Neurol Neurosci; 2008; 26(6):459-65. PubMed ID: 19096133
[TBL] [Abstract][Full Text] [Related]
26. Clinical trials in ALS: an overview.
Turner MR; Parton MJ; Leigh PN
Semin Neurol; 2001 Jun; 21(2):167-75. PubMed ID: 11442325
[TBL] [Abstract][Full Text] [Related]
27. [Skin changes in amyotrophic lateral sclerosis].
Ono S
Brain Nerve; 2007 Oct; 59(10):1099-107. PubMed ID: 17969350
[TBL] [Abstract][Full Text] [Related]
28. Rethinking a drug treatment failure on a traditional ALS target.
Maragakis NJ
Exp Neurol; 2009 Apr; 216(2):254-7. PubMed ID: 19309797
[TBL] [Abstract][Full Text] [Related]
29. Molecular biology of neurotrophic factors.
Sendtner M
Baillieres Clin Neurol; 1995 Nov; 4(3):575-91. PubMed ID: 8599725
[TBL] [Abstract][Full Text] [Related]
30. Are there causal relationships between the development of the inflammatory diseases amyotrophic lateral sclerosis and asthma?
Menendez A; Kuffler D
P R Health Sci J; 2006 Mar; 25(1):51-66. PubMed ID: 16883679
[TBL] [Abstract][Full Text] [Related]
31. Young-onset sporadic amyotrophic lateral sclerosis: a distinct nosological entity?
Gouveia LO; de Carvalho M
Amyotroph Lateral Scler; 2007 Dec; 8(6):323-7. PubMed ID: 17852021
[TBL] [Abstract][Full Text] [Related]
32. Arimoclomol: a potential therapy under development for ALS.
Lanka V; Wieland S; Barber J; Cudkowicz M
Expert Opin Investig Drugs; 2009 Dec; 18(12):1907-18. PubMed ID: 19938902
[TBL] [Abstract][Full Text] [Related]
33. [Regenerative therapies for amyotrophic lateral sclerosis using hepatocyte growth factor].
Aoki M; Warita H; Suzuki N; Kato M; Itoyama Y
Rinsho Shinkeigaku; 2011 Nov; 51(11):1195-8. PubMed ID: 22277532
[TBL] [Abstract][Full Text] [Related]
34. Neurotrophic factors as therapeutic agents in amyotrophic lateral sclerosis. Potential and pitfalls.
Henderson CE
Adv Neurol; 1995; 68():235-40. PubMed ID: 8787235
[No Abstract] [Full Text] [Related]
35. Vitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis.
Camu W; Tremblier B; Plassot C; Alphandery S; Salsac C; Pageot N; Juntas-Morales R; Scamps F; Daures JP; Raoul C
Neurobiol Aging; 2014 May; 35(5):1198-205. PubMed ID: 24378089
[TBL] [Abstract][Full Text] [Related]
36. [Clinical translation of hepatocyte growth factor for amyotrophic lateral sclerosis].
Warita H; Kato M; Suzuki N; Itoyama Y; Aoki M
Rinsho Shinkeigaku; 2012; 52(11):1214-7. PubMed ID: 23196568
[TBL] [Abstract][Full Text] [Related]
37. Neuron saving schemes.
Lindsay RM
Nature; 1995 Jan; 373(6512):289-90. PubMed ID: 7830762
[No Abstract] [Full Text] [Related]
38. Experimental rationale for the therapeutic use of neurotrophins in amyotrophic lateral sclerosis.
Seeburger JL; Springer JE
Exp Neurol; 1993 Nov; 124(1):64-72. PubMed ID: 8282083
[TBL] [Abstract][Full Text] [Related]
39. [Neurotrophic factors and ALS].
Schmalbruch H
Ugeskr Laeger; 1999 May; 161(21):3112-3. PubMed ID: 10377861
[No Abstract] [Full Text] [Related]
40. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop.
Ludolph AC; Bendotti C; Blaugrund E; Hengerer B; Löffler JP; Martin J; Meininger V; Meyer T; Moussaoui S; Robberecht W; Scott S; Silani V; Van Den Berg LH;
Amyotroph Lateral Scler; 2007 Aug; 8(4):217-23. PubMed ID: 17653919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
